Evidence map›Paper›PMID 30160055›Full record

ArticleBrain and behavior2018

Effect of HUK on the outcome of ruptured intracranial aneurysm.

Luyue Chen, Yi Lyu, Xiaoning Lin, Minghui Sun, Wei Feng, Xinhua Tian

Open access · goldAbstract read
In one paragraph

Article in Brain and behavior, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed, 1 pooled it
0.2field-weighted citation impact, top 44% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 1 synthesis or guideline pooled it, 2 citations in OpenAlex.

  1. Pooled it
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 2 institutions in 2 countries.

Luyue ChenDepartment of Neurosurgery, Zhongshan Hospital Xiamen Unviersity, Xiamen, China.
Yi LyuDepartment of Medical Affairs, Techpool Bio-pharma Co., Ltd., Shanghai, China.
Xiaoning LinDepartment of Neurosurgery, Zhongshan Hospital Xiamen Unviersity, Xiamen, China.
Minghui SunDepartment of Medical Affairs, Techpool Bio-pharma Co., Ltd., Shanghai, China.
Wei FengDepartment of Neurosurgery, Zhongshan Hospital Xiamen Unviersity, Xiamen, China.
Xinhua TianDepartment of Neurosurgery, Zhongshan Hospital Xiamen Unviersity, Xiamen, China.ORCID 0000-0001-5244-789X
Zhongshan Hospital of Xiamen University · CNLTT Bio-Pharma (Japan) · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

objectiveTo evaluate the clinical efficacy of Human Urinary Kallidinogenase (HUK) on the outcome of patients with ruptured intracranial aneurysm.

methodsThis was a prospective, open-label study. At the Department of Neurosurgery in our hospital, 127 patients were treated and operated due to ruptured intracranial aneurysm in the period 2015-2016. After surgery, all the patients received basic treatment and 70 patients received additional HUK treatment (HUK group) according to their willing. In detail, 0.15 PNA unit of HUK injection plus 100 ml saline in intravenous infusion was performed, with once a day for 14 consecutive days. The modified Rankin Scale (mRS) scores and favorable mRS rates (mRS 0-1) were analyzed 3-month after the treatment.

resultsNo difference was shown in the basic characteristics between the two groups (p > 0.05). Favorable mRS rate in the HUK group (71.43%) was significantly higher than that in control group (50.88%, p < 0.05). In addition, 3-month death rate was significantly lower in the HUK group. Delayed ischemic stroke rate was similar between the two groups.

conclusionHUK can reduce morbidity and mortality of patients with ruptured intracranial aneurysm after surgery.

Indexed as

AdultAgedAneurysm, RupturedFemaleHumansIntracranial AneurysmKallikreinsMaleMiddle AgedProspective StudiesTreatment OutcomeKallikreinsaneurysmHuman Urinary KallidinogenaseneuroprotectionNeurosurgery

Identifiers

PMID30160055
PMCPMC6192394
OpenAlexW2889312158

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.